5 completed, 2 terminated, 1 no longer available. 4 Phase 1, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 4 |
| Phase 2 | 2 | Terminated 2 |
| Phase 3 | 1 | Completed 1 |
Follow this drug Literature Review of AM0010 trials Research Report on AM0010
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer Pegilodecakin, Nivolumab - Non Small Cell Lung Cancer | Phase 2 | Terminated | Eli Lilly and Company | 52 | 2018-03-22 | 2020-09-11 |
| Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer Pegilodecakin, Pembrolizumab - Non Small Cell Lung Cancer | Phase 2 | Terminated | Eli Lilly and Company | 101 | 2018-03-19 | 2021-01-20 |
| A Crossover Study to Evaluate Pegilodecakin (LY3500518) in Healthy Participants Pegilodecakin - Healthy Adult Subjects | Phase 1 | Completed | Eli Lilly and Company | 12 | 2018-01-19 | 2026-07-13 |
| A 3-Way Crossover Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518) Pegilodecakin - Healthy Adult Subjects | Phase 1 | Completed | Eli Lilly and Company | 12 | 2017-12-18 | 2026-07-07 |
| A Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518) Pegilodecakin - Healthy Adult Subjects | Phase 1 | Completed | Eli Lilly and Company | 24 | 2017-09-05 | 2026-10-02 |
| Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer Pegilodecakin, FOLFOX - Pancreatic Cancer | Phase 3 | Completed | Eli Lilly and Company | 567 | 2017-03-01 | 2020-10-19 |
| A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors Pegilodecakin, Paclitaxel or Docetaxel and Carboplatin or Cisplatin, FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil) - Melanoma, Prostate Cancer | Phase 1 | Completed | Eli Lilly and Company | 353 | 2013-11-15 | 2026-07-09 |
| An Expanded Access Program for AM0010 (Pegilodecakin) AM0010 - Melanoma, Prostate Cancer | No longer available | Eli Lilly and Company | 2020-03-02 |
Carcinoma, Non-Small-Cell Lung (4) · Pancreatic Neoplasms (3) · Breast Neoplasms (2) · Carcinoma, Renal Cell (2) · Colorectal Neoplasms (2) · Melanoma (2) · Ovarian Neoplasms (2) · Prostatic Neoplasms (2) · Neoplasms (1)
United States (7) · Australia (1) · Austria (1) · Belgium (1) · Canada (1) · France (1) · Germany (1) · Italy (1) · Poland (1) · South Korea (1) · Spain (1) · Taiwan (1) · United Kingdom (1)
PMID 33166722, PMID 27528724, PMID 31563517, PMID 32808556, PMID 33555926
2016 (1)